Companies Dominating the Urothelial Carcinoma Treatment Landscape
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- GlaxoSmithKline plc
- Novartis AG
- Dendreon Pharmaceuticals LLC
- Sanofi SA
- F. Hoffmann-La-Roche AG
- UroGen Pharma Ltd
- Koninklijke Philips N.V.
- Olympus Corporation
- AstraZeneca PLC
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of urothelial carcinoma treatment is evaluated at USD 2.01 billion.
The urothelial carcinoma treatment market size was valued at USD 1.47 billion in 2024 and is set to exceed USD 17.9 billion by 2037, expanding at over 21.2% CAGR during the forecast period i.e., between 2025-2037. Raising funding for research and development to develop novel cancer therapies and the growing awareness about bladder diseases will boost the market growth.
North America industry is set to account for largest revenue share of 38% by 2037, attributed to increasing frequency of urothelial carcinoma cancer in the region.
The major players in the market are Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Dendreon Pharmaceuticals LLC, Sanofi SA, F. Hoffmann-La-Roche AG, UroGen Pharma Ltd, Koninklijke Philips N.V., Olympus Corporation, AstraZeneca PLC
